TippingPoint Biosciences develops novel therapeutics by targeting diseases caused by dysfunctional genome chromatin packaging. The company utilizes a platform that targets unstructured regions in chromatin proteins by exploiting unique inter-molecular interfaces specific to disease-driving chromatin states. This approach aims to deliver increased specificity and reduced toxicity for difficult-to-target conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods of drugging chromatin regulatory factors often suffer from toxicity and limited efficacy, hindering their therapeutic potential for diseases linked to chromatin dysfunction. This is due to a lack of specificity in targeting disease-specific chromatin states.
Solution
TippingPoint Biosciences is developing a drug discovery platform that targets the unstructured regions of chromatin proteins to treat diseases caused by dysfunctional genome chromatin packaging. The platform focuses on unique intermolecular interfaces found only in disease-driving chromatin states, increasing specificity and reducing toxicity. By targeting the aberrant chromatin network in disease, TippingPoint aims to develop a new class of molecules to address diseases with high unmet needs, such as cancers and neurodegenerative disorders. This approach is designed to be less susceptible to drug resistance compared to conventional methods.
Target Audience
The primary target audience includes researchers and clinicians focused on developing treatments for cancers and neurodegenerative diseases driven by dysfunctional chromatin networks.
Features
- Targets unstructured regions in chromatin proteins
- Exploits unique intermolecular interfaces found only in disease-driving chromatin states
- Increases drug specificity
- Reduces toxicity
- Designed to be less susceptible to drug resistance
- Focuses on disrupting or restoring protein-protein and protein-DNA networks that package cell genomes
- Recreates the biological context of cancer-driving chromatin states in a controlled, cell-free environment for high-throughput screening